SOX9 is supplied in 50mM Tris-Acetate, pH-7.5, 1mM EDTA and 20% Glycerol.
SOX9 Human Recombinant produced in E.Coli is single, a non-glycosylated, Polypeptide chain containing 150 amino acids (1-150 a.a.) fused to a GST tag and having a total molecular mass of 43kDa. The SOX9 is purified by proprietary chromatographic techniques.
SOX9 is involved in skeletal development. SOX9 regulates the expression of other genes which play a role in chondrogenesis by performing as a transcription factor for these genes. SOX9 takes part in chondrocyte differentiation and, together with steroidogenic factor 1; SOX9 regulates transcription of the anti-Muellerian hormone gene. Deficiencies of SOX9 result in skeletal malformation syndrome campomelic dysplasia, often with sex reversal. SOX9 is a transcription factor having vast mobility group DNA-binding domain that is expressed in all prechondrocytic and chondrocytic cells throughout embryonic growth. SOX9 Phosphorylation by PKA raises its DNA binding and transcriptional activity. SOX9 controls expression of chondrocyte phenotype related genes. IL-1 and TNF-a decrease SOX9 levels of mRNA and/or protein in chondrocytes, therefore strongly inhibit the expression of genes for cartilage extracellular matrix proteins. SOX9 down-regulation takes part in inhibiting expression of the cartilage phenotype in inflammatory joint diseases.
SOX-9, SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal), Transcription factor SOX-9, SOX9, CMD1, SRA1, CMPD1.
Sterile Filtered clear solution.
Store at 4°C if entire vial will be used within 2-4 weeks. Store, frozen at -20°C for longer periods of time. Please avoid freeze thaw cycles.